MedTrace Logo

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

NCT06877650 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2026-01-29

No results posted yet for this study

Summary

This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

JMT108

Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

DRUG

Pembrolizumab

Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

DRUG

Ivonescimab

Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2028-03-30
Completion
2029-03-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06877650 on ClinicalTrials.gov